Page 121 - 南京医科大学学报自然科学版
P. 121
第43卷第9期 沈 楠,高珂梦,黄家晖,等. PET/MR成像在帕金森病中的应用[J].
2023年9月 南京医科大学学报(自然科学版),2023,43(9):1295-1300 ·1299 ·
regional,and national burden of Parkinson’s disease, measured with C ⁃ raclopride and positron emission to⁃
11
1990⁃2016:a systematic analysis for the Global Burden of mography[J]. Ann Neurol,1992,31(2):184-192
Disease Study 2016[J]. Lancet Neurol,2018,17(11): [18] LIU Z Y,LIU F T,ZUO C T,et al. Update on molecular
939-953 imaging in Parkinson’s disease[J]. Neurosci Bull,2018,
[4] GRIMES D,FITZPATRICK M,GORDON J,et al. Canadian 34(2):330-340
guideline for Parkinson disease[J]. CMAJ,2019,191 [19] TATSCH K. Positron emission tomography in diagnosis
(36):E989-E1004 and differential diagnosis of Parkinson’s disease[J].
[5] POSTUMA R B,BERG D,STERN M,et al. MDS clinical Neurodegener Dis,2010,7(5):330-340
diagnostic criteria for Parkinson’s disease[J]. Mov [20] WANG R M,XU B X,GUO Z,et al. Suite PET/CT neuro⁃
Disord,2015,30(12):1591-1601 imaging for the diagnosis of Parkinson’s disease:statisti⁃
[6] KHAN A U,AKRAM M,DANIYAL M,et al. Awareness cal parametric mapping analysis[J]. Nucl Med Commun,
and current knowledge of Parkinson’s disease:a neuro⁃ 2017,38(2):164-169
degenerative disorder[J]. Int J Neurosci,2019,129(1): [21] TEUNE L K,RENKEN R J,MUDALI D,et al. Validation
55-93 of parkinsonian disease⁃related metabolic brain patterns
[7] RAZA C,ANJUM R,SHAKEEL N U A. Parkinson’s [J]. Mov Disord,2013,28(4):547-551
disease:mechanisms,translational models and manage⁃ [22] KON T,TOMIYAMA M,WAKABAYASHI K. Neuropa⁃
ment strategies[J]. Life Sci,2019,226:77-90 thology of Lewy body disease:clinicopathological cross⁃
[8] TRIPATHI M,KUMAR A,BAL C. Neuroimaging in talk between typical and atypical cases[J]. Neuropathology,
parkinsonian disorders[J]. Neurol India,2018,66(Sup⁃ 2020,40(1):30-39
plement):S68-S78 [23] GOMPERTS S N,LOCASCIO J J,MARQUIE M,et al.
[9] LI J,JIN M,WANG L,et al. MDS clinical diagnostic Brain amyloid and cognition in Lewy body diseases[J].
criteria for Parkinson’s disease in China[J]. J Neurol, Mov Disord,2012,27(8):965-973
18
2017,264(3):476-481 [24] SMITH R,SCHOLL M,LONDOS E,et al. F⁃AV⁃1451 in
[10] ZHU L,PLOESSL K,KUNG H F. PET/SPECT imaging Parkinson’s disease with and without dementia and in de⁃
agents for neurodegenerative diseases[J]. Chem Soc Rev, mentia with Lewy bodies[J]. Sci Rep,2018,8(1):4717
2014,43(19):6683-6691 [25] PAJARES M,ROJO A,MANDA G,et al. Inflammation in
[11] NAGASAWA H,TANJI H,ITOYAMA Y,et al. Brain 6⁃ Parkinson’s disease:mechanisms and therapeutic impli⁃
18
[ F]fluorodopa metabolism in early and late onset of Par⁃ cations[J]. Cells,2020,9(7):1687
kinson’s disease studied by positron emission tomogra⁃ [26] VARNAS K,CSELENYI Z,JUCAITE A,et al. PET imag⁃
11
phy[J]. J Neurol Sci,1996,144(1⁃2):70-76 ing of[ C]PBR28 in Parkinson’s disease patients does
[12] MORRISH P K,SAWLE G V,BROOKS D J. Regional not indicate increased binding to TSPO despite reduced
18
changes in[ F]dopa metabolism in the striatum in Par⁃ dopamine transporter binding[J]. Eur J Nucl Med Mol Im⁃
kinson’s disease[J]. Brain,1996,119(6):2097-2103 aging,2019,46(2):367-375
[13] 王慧春,左传涛,黄喆慜,等. C⁃CFT 脑 PET 显像在早 [27] SONIA L,SÉBASTIEN G,CATRIONA W,et al. Increased
11
期帕金森病诊断中的临床应用[J]. 中国临床医学影像 microglial activation in patients with Parkinson disease
18
杂志,2010,21(4):229-232 using[ F]⁃DPA714 TSPO PET imaging[J]. Park Relat
[14]冼文彪,史新冲,张祥松,等.[ C]CFT脑多巴胺转运体 Disord,2021,82:29-36
11
PET 显像对帕金森病诊断和严重程度评估的应用[J]. [28] HALLER S,DAVIDSSON A,TISELL A,et al. MRI of
中国神经精神疾病杂志,2014,40(8):474-478 nigrosome⁃1:a potential triage tool for patients with suspec⁃
[15] 王 坚,蒋雨平,项景德,等. F⁃FP⁃β⁃CIT PET 脑显像 ted parkinsonism[J]. J Neuroimaging,2022,32(2):273-
18
在早期诊断帕金森病中的意义[J]. 中华核医学杂志, 278
2003,23(4):24-26 [29] BAJAJ S,KRISMER F,PALMA J A,et al. Diffusion ⁃
[16] LEE C S,SAMII A,SOSSI V,et al. In vivo positron emis⁃ weighted MRI distinguishes Parkinson disease from the
sion tomographic evidence for compensatory changes in parkinsonian variant of multiple system atrophy:a syste⁃
presynaptic dopaminergic nerve terminals in Parkinson’s matic review and meta⁃analysis[J]. PLoS One,2017,12
disease[J]. Ann Neurol,2000,47(4):493-503 (12):e189897
[17] BROOKS D J,IBANEZ V,SAWLE G V,et al. Striatal D2 [30] PLANETTA P J,SCHULZE E T,GEARY E K,et al. Tha⁃
receptor status in patients with Parkinson’s disease,stria⁃ lamic projection fiber integrity in de novo Parkinson
tonigral degeneration,and progressive supranuclear palsy, disease[J]. AJNR Am J Neuroradiol,2013,34(1):74-79